Puxano

“Accelerating
structure-based
protein research”

PUXANO aims to accelerate structure-based protein research, from sequence to structure

By combining and integrating biotechnology, nanotechnology and data science, PUXANO develops proprietary technology platforms to accelerate structure-based protein research at every step of the workflow, from sequence to structure. Our platforms overcome bottlenecks present in the standard structural biology pipeline such as protein sequence analysis, construct design, expression, purification, quality control and high-resolution structure determination.

Video afspelen

PUXANO services are backed by our proprietary technology platforms

We provide stand-alone services in the form of pre-defined packages at any step of the structural biology pipeline, including protein sequence analysis and construct design, expression and purification, quality control and interaction studies, electron microscopy sample preparation and image acquisition and processing. Backed by our PUXANO technology platforms, many of the bottlenecks encountered with standard technologies are resolved in a single-shot experiment, enabling us to demonstrate the advantages of our platform and to quickly move from an introductory study into a steady collaborative partnership.

From customer to partner

PUXANO aspires to be a long-term partner in your protein research by providing access to our technology platforms and expertise. We thereby transfer from service provider to platform technology provider, where we provide consolidated access to our technology and expertise.  Our aim is not to solve a single structure, but to design a lasting solution for reproducible high-throughput protein structure determination.

Our customers

Internal Target Pipeline

The PUXANO technology platforms are being deployed internally on a selection of  therapeutically relevant yet challenging targets which can not be chracterized using standard technologies. We plan to make these structure-based drug development pipelines available to our partners in the future.